Welcome to our dedicated page for OptimizeRx Corporation news (Ticker: $OPRX), a resource for investors and traders seeking the latest updates and insights on OptimizeRx Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OptimizeRx Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OptimizeRx Corporation's position in the market.
Rhea-AI Summary
OptimizeRx Corp. (Nasdaq: OPRX) announces changes to its Board of Directors, with Gus Halas retiring and Lynn O’Connor Vos assuming the role of Chairperson. The company aims to align with its growth plans, leveraging Vos's expertise in healthcare technology and life sciences to lead the next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
-
Rhea-AI Summary
OptimizeRx Corp. (OPRX) announced preliminary unaudited financials for 2023, with expected revenue exceeding the guidance range of $68-$70 million. The company closed the year with 24 deals, driving a sequential improvement in key performance indicators. Adjusted EBITDA for the fourth quarter is expected to reach a new high, primarily due to a higher margin solution mix. The integration of the Medicx Health acquisition is ahead of expectations, with most activities expected to be completed by the end of the first quarter of 2024. CEO Will Febbo expressed confidence in achieving 2024 revenue guidance of at least $110 million and at least 10% adjusted EBITDA margins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.85%
Tags
-
News
Rhea-AI Summary
OptimizeRx Corp. (OPRX) executives will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 8-11, 2024. The presentation is scheduled for January 11, 2024, at 8:15 a.m. Pacific Time. Management will be available for institutional investor meetings on January 10th and 11th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
Rhea-AI Summary
OptimizeRx Corp. reported Q3 2023 results, with revenue increasing 8% to $16.3 million and gross profit increasing 4% to $9.8 million. GAAP net loss per share was $(0.17), while non-GAAP net income per share was $0.09. The company completed the acquisition of Medicx Health after the quarter ended. OptimizeRx increased its guidance for 2023, expecting revenue between $68-$70 million and adjusted EBITDA between $3-$4 million. Preliminary 2024 guidance expects revenue of at least $110 million with an adjusted EBITDA margin of at least 10%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.31%
Tags
-
Rhea-AI Summary
OptimizeRx Corp. completes acquisition of Medicx Health, expands executive leadership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
-
Rhea-AI Summary
OptimizeRx preannounces preliminary third quarter 2023 results and announces acquisition of Medicx Health
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.01%
Tags
News
Rhea-AI Summary
OptimizeRx Corp. announces a new AI solution, the Dynamic Audience Activation Platform (DAAP), which expands its HCP engagement technology and improves market penetration. In a pilot program, the Company reported a 19% script lift among AI-identified HCPs. Revenue is expected to be tied to DAAP programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
-
Rhea-AI Summary
OptimizeRx announces expansion of its AI-enabled healthcare technology platform through partnerships with EHR providers and a telehealth platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
-
Rhea-AI Summary
OptimizeRx Corp. (OPRX) reported a 186% YOY growth in RWD.AI-enabled portion of the core business, while non-core business lagged. Total revenue was $13.8 million, with a GAAP net loss of $(0.24) per share and non-GAAP net loss of $(0.01) per share for the second quarter of 2023. The company repurchased 526,999 shares at an average price of $14.27 per share in the second quarter of 2023. Cash, cash equivalents, and short-term investments totaled $62.7 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.76%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
OptimizeRx Corporation
Nasdaq:OPRX
OPRX Rankings
OPRX Stock Data
220.33M
15.06M
11.86%
72.33%
3.61%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
United States of America
WALTHAM
About OPRX
optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.